de Duve Institute, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology (WELBIO), UCLouvain, Brussels, Belgium.
J Inherit Metab Dis. 2020 Jan;43(1):14-24. doi: 10.1002/jimd.12187. Epub 2019 Dec 29.
It is traditionally assumed that enzymes of intermediary metabolism are extremely specific and that this is sufficient to prevent the production of useless and/or toxic side-products. Recent work indicates that this statement is not entirely correct. In reality, enzymes are not strictly specific, they often display weak side activities on intracellular metabolites (substrate promiscuity) that resemble their physiological substrate or slowly catalyse abnormal reactions on their physiological substrate (catalytic promiscuity). They thereby produce non-classical metabolites that are not efficiently metabolised by conventional enzymes. In an increasing number of cases, metabolite repair enzymes are being discovered that serve to eliminate these non-classical metabolites and prevent their accumulation. Metabolite repair enzymes also eliminate non-classical metabolites that are formed through spontaneous (ie, not enzyme-catalysed) reactions. Importantly, genetic deficiencies in several metabolite repair enzymes lead to 'inborn errors of metabolite repair', such as L-2-hydroxyglutaric aciduria, D-2-hydroxyglutaric aciduria, 'ubiquitous glucose-6-phosphatase' (G6PC3) deficiency, the neutropenia present in Glycogen Storage Disease type Ib or defects in the enzymes that repair the hydrated forms of NADH or NADPH. Metabolite repair defects may be difficult to identify as such, because the mutated enzymes are non-classical enzymes that act on non-classical metabolites, which in some cases accumulate only inside the cells, and at rather low, yet toxic, concentrations. It is therefore likely that many additional metabolite repair enzymes remain to be discovered and that many diseases of metabolite repair still await elucidation.
传统观点认为,中间代谢酶具有极高的特异性,这足以防止无用和/或有毒的副产物的产生。最近的研究表明,这种说法并不完全正确。实际上,酶并非严格特异的,它们通常对细胞内代谢物表现出较弱的侧活力(底物混杂性),类似于它们的生理底物,或者对其生理底物缓慢催化异常反应(催化混杂性)。因此,它们会产生不能被常规酶有效代谢的非经典代谢物。在越来越多的情况下,正在发现代谢物修复酶,用于消除这些非经典代谢物并防止其积累。代谢物修复酶还消除了通过自发(即非酶促)反应形成的非经典代谢物。重要的是,几种代谢物修复酶的遗传缺陷导致“代谢物修复的先天性错误”,例如 L-2-羟戊酸尿症、D-2-羟戊酸尿症、“普遍存在的葡萄糖-6-磷酸酶”(G6PC3)缺乏症、糖原贮积病 Ib 型中存在的中性粒细胞减少症或修复 NADH 或 NADPH 的水合形式的酶的缺陷。代谢物修复缺陷可能难以识别,因为突变酶是非经典酶,作用于非经典代谢物,在某些情况下,这些代谢物仅在细胞内积累,并且浓度相当低,但具有毒性。因此,很可能还有许多其他代谢物修复酶有待发现,许多代谢物修复疾病仍有待阐明。